TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06452719
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 10 mg orally daily for three consecutive days
Study: NCT06452719
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
Study: NCT05354856
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
Study: NCT05375994
Drug: avutometinib (VS-6766) and adagrasib
Normalized name: Adagrasib
DrugBank: Avutometinib (DB15254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
Study: NCT05978050
Drug: nimotuzumab plus paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
Study: NCT04369014
Drug: etomidate anesthesia
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etomidate is used for induction and maintenance of general anesthesia
Study: NCT05978050
Drug: placebo plus paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
Study: NCT04369014
Drug: propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol is used for induction and maintenance of general anesthesia
Study: NCT05462938
Drug: Continuous infusion of propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedation under continuous infusion of propofol. Small doses of fentanyl will be administered if needed.
Study: NCT05462938
Drug: Continuous infusion of dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation under continuous infusion of dexmedetomidine. Small doses of fentanyl will be administered if needed.
Study: NCT04806893
Drug: lerodalcibep
Normalized name: Lerodalcibep
DrugBank: Lerodalcibep (DB19071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg subcutaneous injection every month (Q4W)
Study: NCT05429762
Drug: Tusamitamab ravtansine
Normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion
Study: NCT04713631
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.
Study: NCT04713631
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
Study: NCT05207514
Drug: Nanoxel M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Study: NCT05207514
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Study: NCT06332079
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Target agent
Study: NCT00249132
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06332079
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target agent
Study: NCT06332079
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT06332079
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Target agent
Study: NCT05416021
Drug: dapivirine
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dapivirine vaginal ring
Study: NCT05800938
Drug: Isosorbid mononitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imdur tablets were given twice daily for 4 weeks
Study: NCT06383897
Drug: HS-10398
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction
Study: NCT05801289
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Giving the drug to group Q
Study: NCT05389930
Drug: THC-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis with 9.53% THC and 0.09% CBD
Study: NCT05389930
Drug: CBD-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis with 0.35% THC and 11.27% CBD
Study: NCT05389930
Drug: Cannabis placebo
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked placebo cannabis plant material
Study: NCT05389930
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drink containing 0.3 g/kg of alcohol
Study: NCT06575257
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg orally twice daily for 12 weeks before radical prostatectomy
Study: NCT06575257
Drug: Goserelin 3.6 mg
Normalized name: goserelin 3.6 MG
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6 mg goserelin hypodermic once per 4 weeks
Study: NCT03674320
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
Study: NCT04945148
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
Study: NCT04945148
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
Study: NCT05361655
Drug: Palbociclib + an aromatase inhibitor
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib + an aromatase inhibitor therapy
Study: NCT06482190
Drug: RSN0402 Part 1
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single ascending doses of 2mg, 4mg, 8mg, 12 mg, and 16mg of RSN0402 or placebo on Day 1 for Cohort 1 to 5. Cohort 2(4mg) will also a single dose of 150 mg nintedanib soft capsule will be administered orally after at least 7-days washout period.
Study: NCT06482190
Drug: RSN0402 Part 2
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive multiple ascending doses of 4mg ,8mg,12mg ,16mg of RSN0402 or placebo administered once daily from Day 1 to Day 7 for Cohort 6 to 9.
Study: NCT04932655
Drug: simufilam
Normalized name: Simufilam
DrugBank: Simufilam (DB18817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
Study: NCT05506566
Drug: 68Ga-FAP-CHX
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
Study: NCT05506566
Drug: 68Ga-FAP-CHX
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
Study: NCT06450392
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/mL (manufactured concentration) local TXA injection in the orbit
Study: NCT06450392
Drug: Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)
Normalized name: tranexamic acid in NaCl,iso-os 1,000 mg/100 mL (10 mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g IV TXA
Study: NCT06450392
Drug: normal saline - injection
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline injection in the orbit
Study: NCT06450392
Drug: normal saline - intravenous
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% IV Normal Saline
Study: NCT05458401
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No drug will be administered during this study.
Study: NCT06577194
Drug: Sintilimab + IL-2 Combined with Capox
Normalized name: miconazole
DrugBank: Sintilimab (DB15765)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sintilimab + IL-2 Combined with Capox
Study: NCT06188871
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two injections of 300mg dupilumab, subcutaneous 14 days apart
Study: NCT04671875
Drug: Recombinant Humanized Monoclonal Antibody MIL93
Normalized name: Recombinant humanized monoclonal antibody 5c8
DrugBank: Ruplizumab (DB06475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I.
Study: NCT05931042
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
Study: NCT05347576
Drug: CKD-393(2)
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06497894
Drug: Hormone Replacement Therapy (HRT)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.
Study: NCT04454476
Drug: Trametinib treatment
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg taken by mouth once a day for 14 days
Study: NCT04929392
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04929392
Drug: Lenvatinib Mesylate
Normalized name: Lenvatinib Mesylate
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04929392
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06221241
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: capsules for oral administration.
Study: NCT04666701
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tablet
Study: NCT04666701
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine dragee
Study: NCT04580134
Drug: clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biotype 1 and Biotype 2
Study: NCT04580134
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Biotype 1 and Biotype 2
Study: NCT06185179
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be distributed in 500mg pills.
Study: NCT04762979
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib 300mg, PO, days 1-28 of each cycle.
Study: NCT04762979
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500mg, IM, once monthly
Study: NCT06176404
Drug: Stellate ganglion block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for SGB. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05745142
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: as provided in real world practice
Study: NCT06197438
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
Study: NCT06197438
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
Study: NCT06197438
Drug: Levo-Leucovorin
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
Study: NCT06197438
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
Study: NCT06197438
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.
Study: NCT06197438
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.
Study: NCT04679350
Drug: Placebo (Normal saline solution)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
Study: NCT05692830
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
Study: NCT05539287
Drug: Lactobacillus-Based Capsule
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
Study: NCT05131438
Drug: sugemalimab
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugemalimab (Anti-PD-L1 antibody)
Study: NCT05028556
Drug: Cohort 1 of Y101D
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y101D, 1mg/kg, Q2W, intravenous infusion
Study: NCT05028556
Drug: Cohort 2 of Y101D
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y101D, 3mg/kg, Q2W, intravenous infusion
Study: NCT05028556
Drug: Cohort 3 of Y101D
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y101D, 10mg/kg, Q2W, intravenous infusion
Study: NCT05028556
Drug: Cohort 4 of Y101D
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y101D, 20mg/kg, Q2W, intravenous infusion
Study: NCT05028556
Drug: Cohort 5 of Y101D
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y101D, 30mg/kg, Q2W, intravenous infusion
Study: NCT06004921
Drug: AB801
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05433532
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
Study: NCT05433532
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
Study: NCT05433532
Drug: Flumatinib
Normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumatinib: 600mg qd, d4-d21, oral
Study: NCT05207657
Drug: Lentiviral vector transduced CD34+ cells
Normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
Study: NCT06455293
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring
Study: NCT06129916
Drug: long-acting depot buprenorphine (LADB)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
Study: NCT06416891
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCPB using 10 ml of bupivacaine 0.25%
Study: NCT06416891
Drug: dexamethasone 2 mg in bupivacaine 0.25%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCPB using dexamethasone 2 mg in 10 ml of bupivacaine 0.25%
Study: NCT06576440
Drug: Ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive a subcutaneous injection of acyl-ghrelin as the active condition.
Study: NCT06576440
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this arm will receive a subcutaneous injection of saline as placebo control condition.